{"symbol":"BMY","fiscalQuarter":"Q3-2017","reportDate":"2017-10-26","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q3-2017","postBrief":{"headline":"Bristol Myers Squibb Misses on EPS \u2014 Stock Down 4.77%","keyNumbers":[{"metric":"EPS","actual":"$0.75","expected":"N/A","surprise":"-3.49%"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["We are focused on maintaining our current pipeline and addressing market challenges.","Our commitment to innovation remains strong despite current pressures."],"summary":"Management expressed concerns about market conditions impacting performance. They emphasized their ongoing commitment to their product pipeline."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a significant drop in stock price. Investors may be concerned about the company's ability to navigate current market challenges and the lack of guidance could add to uncertainty. The stock's decline reflects these worries as the company looks to stabilize its performance moving forward.","metaDescription":"Bristol Myers Squibb (BMY) Q3 2017 earnings: EPS missed expectations. Stock down 4.77%. Full breakdown."}}